All Title Author
Keywords Abstract


Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients

DOI: http://dx.doi.org/10.2147/IDR.S22587

Keywords: invasive fungal infections, immunocompromised hosts, empiric therapy, polyenes, efficacy and safety

Full-Text   Cite this paper   Add to My Lib

Abstract:

fety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients Review (3376) Total Article Views Authors: Miceli MH, Chandrasekar P Published Date January 2012 Volume 2012:5 Pages 9 - 16 DOI: http://dx.doi.org/10.2147/IDR.S22587 Received: 16 November 2011 Accepted: 02 December 2011 Published: 11 January 2012 Marisa H Miceli1, Pranatharthi Chandrasekar2 1Oakwood Hospital and Medical Center, Dearborn, 2Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI, USA Abstract: Liposomal amphotericin B is a "true" liposomal formulation of amphotericin B with greatly reduced nephrotoxicity and minimal infusion-related toxicity. This broad spectrum polyene is well tolerated and effective against most invasive fungal infections. In view of the current limitations on diagnostic capability of invasive fungal infections, most clinicians are often compelled to use antifungal drugs in an empiric manner; liposomal amphotericin B continues to play an important role in the empiric management of invasive fungal infections, despite the recent availability of several other drugs in the azole and echinocandin classes.

Full-Text

comments powered by Disqus